+

WO2001008725A1 - Dispositif d'administration pharmaceutique et utilisation de celui-ci - Google Patents

Dispositif d'administration pharmaceutique et utilisation de celui-ci Download PDF

Info

Publication number
WO2001008725A1
WO2001008725A1 PCT/US2000/020240 US0020240W WO0108725A1 WO 2001008725 A1 WO2001008725 A1 WO 2001008725A1 US 0020240 W US0020240 W US 0020240W WO 0108725 A1 WO0108725 A1 WO 0108725A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical
conduit
proximal end
fiowingly
distal end
Prior art date
Application number
PCT/US2000/020240
Other languages
English (en)
Inventor
David S. Silva
Original Assignee
Silva David S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silva David S filed Critical Silva David S
Priority to AU63743/00A priority Critical patent/AU6374300A/en
Publication of WO2001008725A1 publication Critical patent/WO2001008725A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0693—Brain, cerebrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1042—Alimentary tract
    • A61M2210/1075—Gall bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/16804—Flow controllers
    • A61M5/16813—Flow controllers by controlling the degree of opening of the flow line

Definitions

  • the present invention relates in general to pharmaceutical delivery devices and in particular to an apparatus for pharmaceutical deliver and the use thereof.
  • Effective drug therapy encompasses much more than selecting a proper medicament to ameliorate symptoms. Physicians and pharmacists must also consider how medicament reaches its target site before being inactivated or eliminated. Thus, it is preferable to deliver the medicament locally at the target site if possible.
  • the ability to treat a disease affecting the brain requires either a pharmaceutical capable of penetrating the blood-brain barrier or the implanting of a device able to deliver the pharmaceutical directly to the brain.
  • the invention described herein involves a pharmaceutical delivery device capable of delivering a pharmaceutical locally to a target.
  • a pharmaceutical delivery device capable of delivering a pharmaceutical locally to a target.
  • Examples of such pharmaceutical delivery devices include: Howard (U.S. Patent No. 5,676,655), Laske (U.S. Patent No. 5,720,720), the Elsberry patents (U.S. Patent Nos. 5,735,814, 5,814,014, and 5,846,220), Rise (U.S. Patent No. 5,782,798), and Dreessen (U.S. 5,843,150).
  • Howard discloses a method for implanting a neuroprosthetic pharmaceutical delivery apparatus into a target zone of a patient's brain for the purpose of reducing or eliminating defects from tinnitus.
  • the apparatus includes a catheter inserted into either the patient's auditory cortex or thalamus.
  • the catheter through the assistance of an injectable pharmaceutical reservoir pump (e.g., Medtronics pump or an Alzet pump), microinfuses pharmaceuticals that suppress or eliminate abnormal neuroactivity in geographically separate locations of the patient's brain, eliminating the symptoms of tinnitus.
  • an injectable pharmaceutical reservoir pump e.g., Medtronics pump or an Alzet pump
  • Laske (5,720,720) introduces a method for high-flow microinfusion that provides convection-enhanced delivery of agents into the brain and other solid tissue structures.
  • the method requires the positioning of the tip of a diffusion catheter within the target tissue area and supplying a pharmaceutical agent through the catheter, while maintaining a pressure gradient from the tip of the catheter.
  • the infusion catheter includes a plurality of elongated slits adjacent to a tapered portion of the catheter. The slits are parallel to the axis of the catheter and spaced symmetrically about the circumference.
  • a pump e.g. syringe pump, Model 22 Harvard
  • the Elsberry Patents 5,735.814 and 5,814.014 introduce a technique for infusing pharmaceuticals into the brain to treat neurodegenerative disorders.
  • the technique employs the use of an implantable pump and catheter.
  • the implantable pump is a mechanical pump comprising a motor and is further described in U.S. Patent No. 4,692,147.
  • the Elsberry Patent (,846,220) describes a specific method for treating Alzheimer's disease.
  • the method comprises delivering the pharmaceutical agents indomethacin or nonsteroidal anti-inflammatory agents having a cyclooxygenase inhibitor action directly to the hippocampus or the lateral ventricle of the brain.
  • the apparatus for delivering the pharmaceutical agents consists of a catheter having a flexible distal end that is implanted directly into the hippocampus or lateral ventricle.
  • the apparatus also includes a pump coupled to the catheter for delivering the pharmaceutical agents to the hippocampus or lateral ventricle.
  • Rise (5,783,798) introduces a technique for using one or more pharmaceuticals for treating an eating disorder by means of using an implantable pump and catheter.
  • the catheter is surgically implanted in the brain so that the distal end resides at the target site for pharmaceutical infusion.
  • the proximal end of the catheter attaches to a mechanical infusion pump like the one described in U.S. Patent No. 4,692,147.
  • Dreessen 5,843,150 describes a device and method for providing electrical and/or fluid treatment to a patient's brain.
  • the device comprises a lead (e.g. catheter) and a pump, similar to the Medtronic Synciro Med pump.
  • a common feature in all of the above described pharmaceutical delivery devices is the use of a pump.
  • One common type of pump is the mechanical pump.
  • a motive force is applied to a liquid, which expels the liquid from the body of the pump.
  • Battery-operated motors, inflated balloons, and the vapor pressure of volatile liquids are typically used to provide the motor force to drive such pumps.
  • mechanical pumps suffer from particular disadvantages: complexity, expense, and fallibility.
  • a second type of pump is an osmotic pump.
  • a common type of osmotic pump includes a chamber containing water, a chamber containing salt, and a chamber containing a pharmaceutical agent.
  • the water chamber is separated from the salt chamber by a rigid membrane that is permeable to water but not to salt.
  • the salt chamber is separated from the chamber containing the pharmaceutical agent by an impermeable partition, typically an impermeable resilient membrane.
  • water flows through the rigid membrane to the salt chamber increasing the volume of the salt chamber and exerting pressure on the resilient membrane between the salt chamber and the chamber containing the pharmaceutical agent. The volume of the chamber containing the pharmaceutical agent is thereby reduced and expelled from the pump.
  • osmotic pump A primary example of an osmotic pump is the Alzet Osmotic Pump (see http://www.alzet.com.).
  • the major disadvantages of osmotic pumps are their complexity and cost.
  • the invention described herein introduces a pharmaceutical delivery device that requires no pump. Rather, the delivery device utilizes an endogenous pressure of the body to create a flow of the pharmaceutical to the target site.
  • the delivery device comprises a first conduit having a distal end and a proximal end wherein the distal end is positioned within an area of the brain accessible to cerebral spinal fluid (CSF).
  • CSF cerebral spinal fluid
  • the proximal end of the distal conduit is secured to a structure capable of serving as a pharmaceutical reservoir.
  • a second conduit having a distal end and a proximal end, is attached to the pharmaceutical reservoir at its proximal end.
  • the distal end of the second conduit is positioned at a target site in the brain where a pharmaceutical agent is to be delivered.
  • a shunt can also be positioned at the target site to maintain a positive flow into the target site and preclude the likelihood of edema in the brain.
  • a variety of types of pharmaceutical agents can be administered through the novel pharmaceutical device described herein. Examples include but are not limited to: commonly manufactured pharmaceuticals, emulsified pharmaceuticals, living cells that produce a therapeutic product, gene products, DNA, plasmids designed to alter genetic signals, dyes or markers used for diagnostics, endogenous or exogenous proteins intended to alter or affect the target tissue, growth factors, hormones, second messengers, or mRNA, etc.
  • Other novel characteristics of the invention which include not only the physical structure of the device but its method of operation, together with further objects and advantages of the invention, will be better understood from the following descriptions and figures.
  • Each figure of a preferred embodiment is merely intended to illustrate the invention by way of example.
  • the drawings are for illustration and enabling purposes only, and therefore not intended in any fashion to be a definition of the limits of the invention.
  • a pharmaceutical delivery device wherein a pharmaceutical agent can be continuously delivered to a target site within the body without the cost and complexity associated with other types of delivery devices.
  • the pharmaceutical delivery device herein utilizes an endogenous pressure of the body to move the therapeutic composition from a reservoir to the target site.
  • the device can be used anywhere a pressure gradient can be found in the body (i.e. cerebral spinal fluid, blood flow, digestive device, etc.).
  • the principles of the present invention disclose that the pharmaceutical delivery device as described herein may also encompass a pressure modulating component and may be synthesized of biodegradable materials.
  • FIGURES 1A and IB are a top- and side-view of a pharmaceutical delivery device without any modifications
  • FIGURE 2 is a partially sectional view of a valve assembly
  • FIGURE 3 is another partially sectional view of a valve assembly
  • FIGURE 4 is a partially sectional view of conduits having a micro dialysis tip
  • FIGURE 5 is a partially sectional view of conduits having a loop dialysis tip
  • FIGURE 6 is another partially sectional view of conduits having another type of loop dialysis tip;
  • FIGURE 7 is a partially sectional view of a conduit aligned in a linear-flow dialysis
  • FIGURE 8 is sagittal view of a human brain, which illustrates the use of the pharmaceutical delivery device
  • FIGURE 9 is a view of the device and its modifications for use in delivering pharmaceuticals to the coronary region
  • FIGURE 10 is an enlarged view of the pharmaceutical delivery device as it can be used in the cardio-vascular system;
  • FIGURE 11 illustrates the use of the device with its modifications in connection with the digestive system;
  • FIGURE 12 is a partially sectional view of the target infuser
  • FIGURE 13 is a side-view of an attachment to the device wherein the attachment provides for a dynamic endogenous pressure and means for maintaining a consistent flow rate from the lateral ventricle to a target site in the brain;
  • FIGURE 14 is an enlarged view of the means of isolating flow between the target site and shunt flow within the target infuser.
  • a pharmaceutical delivery device which permits for the delivery of pharmaceuticals to the brain and other regions of the body, is described wherein the device can continuously deliver a fluid-like therapeutic composition (which can comprise a pharmaceutical agent) to a target site within the body without the cost and complexity associated with other types of delivery devices.
  • a fluid-like therapeutic composition which can comprise a pharmaceutical agent
  • the pharmaceutical delivery device herein utilizes an endogenous pressure of the body to move the therapeutic composition from a reservoir to the target site.
  • the device can be used anywhere a pressure gradient can be found in the body (i.e. cerebral spinal fluid, blood flow, digestive device, etc.).
  • An embodiment of the pharmaceutical delivery device described herein can be of numerous components and arrangements thereof. Although various embodiments exist for the pharmaceutical delivery device, preferred embodiments and the use thereof are depicted in FIGURES 1-14.
  • FIGURES 1A and IB depict a top- and side-view of the configuration of a pharmaceutical delivery device 10. It should be noted that actual physical embodiments of the apparatus disclosed in the present figures may be scaled differently depending on the application; the scaling of the present figures is therefore for illustrative purposes only. Additionally, edges shown in the figures may be rounded or smoothed and tubular structures may have elliptical or polygonal cross-sections, as well as circular cross-sections.
  • the device 10 comprises a central assembly 20. a valve assembly 30, a first conduit 80, target dialysis membrane 100, a second conduit 110, a target infuser 135, a third conduit 150, a fourth conduit 175, and a shunt 200.
  • the conduits 80, 1 10. 150 and 175 can be treated as one continuous conduit. These conduits, either independently or collectively, can be a cannula, catheter or a form of tubing.
  • the conduits 80, 110, 150, 175, shunt 200, target infuser 135, central assembly 20, and valve assembly 30 are preferably made from biodegradable materials known to those skilled in the art.
  • Preferred biodegradable materials can be generally classified into eight groups, which include:[l] biodegradable linear aliphatic polyesters and their copolymers (i.e., polyglycolide, polylactide, polycaprolactone, polyhydroxybutyrate), [2] copolymers of these and other monomers including poly(glycolide-trimethylene-carbonate), poly(L-lactic acid-L-lysine) and others; [3] polyanhidrides, [4] poly(orthoesters), [5] poly(ester-ethers) like poly(p-dioxanone); [6] biodegradable polysaccarides like hyaluronic acid, chitin and chitosan; [7] poly-amino acids like poly-L-glutamic acid and poly
  • Materials can be selected by their crystallinity as single polymers or copolymer, polymer mixtures, or situations where different parts of the device are manufactured of different polymers to achieve the desired biodegradation of the device for the duration of a treatment period. Materials can be selected based on their method of degradation, which includes but is not limited to hydrolysis, enzyme degradation, or photodegradation depending on the photosource. This list of acceptable biodegradable polymers should not be construed as exhaustive. Additionally, the length of the expected course of treatment (e.g., weeks, months or years) is a factor in selecting the biodegradable material.
  • the forming of the pharmaceutical drug delivery device 10 from the biodegradable materials typically involves heating the material to their melting point. The material can then be cased. shaped, molded, extruded or machined, or similarly manipulated using a solvent system.
  • central assembly 20 comprises a pharmaceutical depot 25. which is capable of supporting a pre-dissolution solid or fluid-like therapeutic composition 27. This composition can be combined with numerous medicaments needed to treat the tissue at target site 500.
  • the pharmaceutical depot 25 is fiowingly engaged at its distal end 28 to conduit 110. At the proximal end 29 of pharmaceutical depot 25, the pharmaceutical depot 25 is fiowingly engaged to valve assembly 30.
  • valve assembly 30 is fiowingly engaged to proximal end 85 of conduit 80 by attachment member 50.
  • a filter 51 constructed for example of Teflon or PTFE, positioned downstream from pharmaceutical depot 25 for filtering out particulates.
  • valve assembly 30 can be fiowingly engaged to distal end 28 of conduit 110 by attachment member 50.
  • attachment member 50 is an elbow joint made from the biodegradable materials previously discussed.
  • the distal end 90 of conduit 80 resides in an area of the body where an endogenous pressure resides, thus connecting central assembly 20 to a portion of the body that produces an endogenous pressure (FIGURES 8, 9, 10, and 11 provide different examples of endogenous pressures located in the body).
  • the inner surfaces of depot 25 and conduits 80, 110, 150 and 175 are lined or coated with a material which inhibits the adhesion of living cells, platelets and other organic and inorganic particulates thereto.
  • Valve assembly 30 as depicted in FIGURES 1. 2 and 3, comprises an inner cylindrical component 31, an outer cylindrical component 32, adjustable valve 35, a plurality of openings 36, 37, 38, means 40 for adjusting valve 35, and gasket 45.
  • a preferred means for adjusting valve 35 is the use of an adjuster knob 40 as illustrated in FIGURE 1.
  • Other preferred means for adjusting valve 35 is a control device 250 electrically wired to the valve 35 or a wireless remote control having a receiver device on the valve 35.
  • Gasket 45 prevents the leakage of fluid from valve 35 at adjuster knob 40.
  • Inner cylindrical component 31 is rotationally engaged in the outer cylindrical component
  • the inner cylindrical component 31 can rotate within the outer cylindrical component 32, which remains static with respect to central assembly 20.
  • the outer cylindrical component 32 acts as a gasket sealing the entire surface area of inner cylindrical component 31.
  • One end of the cylindrical component 32 is closed (end 41) as the other remains open (end 42) to receive the endogenous fluid creating the pressure that drives the pharmaceutical delivery device 10.
  • FIGURE 3 the outer cylindrical component 32 is depicted more definitively.
  • the outer cylindrical component 32 comprises at least one opening 33, which is fiowingly engaged to the pharmaceutical depot 25. Open end 42 receives the endogenous fluid flowing from conduit 80 through attachment member 50, and into inner cylindrical component 31.
  • the plurality of openings 36, 37, and 38 of inner cylindrical component 31 are of various sizes.
  • the various sizes of the openings assist in controlling the amount of endogenous fluid entering into the pharmaceutical depot 25.
  • Opening 36 has an area which is greater than opening 37, which is greater than the area of opening 38.
  • the operator can select either openings 36, 37 or 38 to control the amount of endogenous fluid (pressure) entering the pharmaceutical depot 25.
  • the operator can elect to use only a portion of the openings 36, 37, and 38 to more finely control the endogenous fluid flow (pressure) into the pharmaceutical depot 25.
  • the type of valve, number or size of openings merely illustrate a possible means to control flow.
  • This object 32 is merely illustrative of a valve component capable of controlling the flow of fluid into 25.
  • the distal end 28 of the central assembly 20 attaches to a proximal end 115 of conduit 110.
  • valve 35 When valve 35 is open (i.e. one of openings 36, 37, or 38) and aligned with the opening 33 at outer cylindrical component 32 and the opening at the proximal end 29 of pharmaceutical depot 25, the fluid-like therapeutic composition 27 flows from pharmaceutical depot 25 into conduit 110.
  • the conduit 110 has a distal end 120 that is fiowingly engaged to a target infuser 135.
  • the target infuser 135 is preferably made from the biodegradable materials as previously discussed.
  • Target infuser 135 is further depicted in FIGURE 12.
  • target infuser 135 specifically attaches to conduit 1 10 via attachment member 400.
  • a gasket 405 is adhered to the attachment member 400, which further connects the attachment member 400 to the bypass tubing 410.
  • Bypass tubing 410 includes a space 420 wherein the fluid-like therapeutic composition 27 flows through and into conduit 150.
  • the distal end 425 of bypass tubing 410 completely encompasses conduit 150 and is closed.
  • Bypass tubing 410 contains two (2) openings 480 and 490, which are specifically illustrated in FIGURE 14. Opening 480 is of a diameter such that conduit 175 can be securely attached within opening 480 during operation of device 10.
  • Opening 490 is of a diameter such that conduit 150 can be securely attached within opening 480 during operation of device 10.
  • Bypass tubing 410 is of a size such that the shown space tubing receives bypass tubing 410, in a manner such that 410 is equidistant from the luminal, paillar surface of 430.
  • the flow of fluid-like therapeutic composition 27 travels through bypass tubing 410, via conduit 110 and into the conduit 150 where it enters target site 500 through dialysis membrane 100 (See FIGURES 4-7 hereinafter for a more specific discussion). Excess fluid at target site 500 can travel through dialysis membrane 100 and into conduit 175.
  • conduit 175 the excess fluid enters shunt space tubing 430 at cavity 440 and flows into shunt 200, which extends to an area of lower pressure within the body or to the exterior surface of the body.
  • An outer covering 450 encases the bypass tubing 410 and shunt space tubing 430.
  • the shunt 200 is fixably attached to the outer covering 450.
  • FIGURE 4 depicts a microdialysis tip comprising a dialysis membrane 100 at the distal ends 160 and 177 of respective conduits 150 and 175. (It should be noted that the bifurcation of conduits 150 and 175 can also take place outside the tissue, with their subsequent convergence near the target area).
  • the fluid-like therapeutic composition 27 flows from the pharmaceutical depot 25 into the conduit 150 and through the dialysis membrane 100 to the target site 500.
  • conduit 175 has a smaller circumference than conduit 150 and can therefore more readily receive excess flow.
  • Conduit 175 extends from the target site 500 to a shunt 200 where the excess fluid is extracted to a region of the body having lower pressure or from the body entirely.
  • the length of inner conduit 175 can be of variable lengths depending on the pressure and tissue density located at the target site 500.
  • the inventor refers the reader to Laske (U.S. Patent 5,720,720) for an understanding of diffusion rates into various tissue type, in particular brain tissue.
  • FIGURE 5 depicts a loop dialysis tip at the distal end 160 and 177 of respective conduits 150 and 175.
  • a fitting 180 separates conduits 150 and 175 at their respective distal ends.
  • the fitting 180 is preferably made of a biodegradable material as previously discussed.
  • support 190 which is also preferably derived of a similar biodegradable material as previously discussed extends along the outer surface of conduits 150 and 175.
  • the fluid-like composition 27 flows through conduit 150 through dialysis membrane 100 into the target site 500.
  • the internal pressure at the target site 500 can be relieved by allowing excess fluid at target site 500 to flow back through dialysis membrane 100, through conduit 175 and into shunt 200 where the excess fluid is extracted to a region of the body having lower pressure or from the body entirely.
  • the dialysis tip depicted in FIGURE 6 is similar to the dialysis tip described in FIGURE
  • the conduit 175 of FIGURE 6 has a smaller circumference than the conduit 175 of FIGURE 5. This is to assist in removing excess fluid more readily from target site 500. Additionally, the smaller conduit 175 of FIGURE 6 resides within a separate conduit 190 which extends approximately to the target infuser 135. The purpose of positioning conduit 175 into conduit 190 is to alter the flow of fluid from the target site 500 and provide another means that can assist in adjusting the pressure at the target site 500.
  • FIGURE 7 depicts yet another type of flow dialysis.
  • conduit 150 attaches to dialysis membrane 100 at its distal end 160 preferably by a sealant 105.
  • a preferred sealant can be methylacrylate vet-bond or SuperGlue®, although any sealant that is inert to the body and maintains a strong bond would suffice.
  • Dialysis membrane 100 extends linearly from conduit 150 to shunt 200.
  • Shunt 200 extends to the outer surface of the body and is fixably attached to structural support 198 by a sealant similar to sealant 105.
  • Dialysis membrane 100 extends beyond the proximal end 201 of the shunt 200 and attaches to structural supports 198 by sealant 105.
  • shunt 200 does not reside at target infuser 135, but proceeds immediately to a low pressure location.
  • the linear flow dialysis as illustrated in FIGURE 7, allows for the flow of fluid-like therapeutic composition 27 to diffuse through dialysis membrane 100 to target site 500.
  • the pressure at the target site 500 is maintained at a relatively constant level as a result of the excess fluid being taken up by dialysis membrane 100 and vacated into shunt 200, where the excess fluid is extracted to a region of the body having lower pressure or from the body entirely.
  • pharmaceutical delivery device 10 can further comprise a pressure modulating component (PMC) 300.
  • the PMC 300 provides for a dynamic endogenous pressure that may be present within the cerebral spinal device under extraordinary movement or acceleration of forces.
  • PMC 300 as depicted in FIGURE 13 is fiowingly engaged to pharmaceutical delivery device 10.
  • the preferred embodiment of the PMC 300 as depicted in FIGURE 13 comprises an electronic control device 305, a balloon carrier cannula 310. a first conduit 340, pressure sensor 375 and a balloon-like apparatus 390.
  • cerebral spinal fluid travels from the conduit 80 through valve assembly 30 and into pharmaceutical depot 25, where the CSF contacts a pressure sensor 375.
  • the pressure sensor 375 is securely attached within the pharmaceutical depot 25.
  • fluid flow should be laminar rather than turbulent to prevent clotting (if blood pressure is the drawing force), bubbles or other impediments.
  • the CSF drives the fluid-like therapeutic composition 27 within pharmaceutical depot 25 past barrier 800.through the conduit 110 and into target infuser 135. From the target infuser 135, the therapeutic composition 27 flows into conduit 150, through dialysis membrane 100 and into the target site 500.
  • the pressure sensor 375 records the pressure within pharmaceutical depot 25 and transmits this recording to the control device 305, which has a preset pressure level in which the pressure sensor recordings are compared.
  • a balloon-like structure 390 can be discharged into the ventricular system and inflated or deflated to maintain the desired preset pressure level previously input in control device 305.
  • the balloon-like apparatus 390 can inflate and deflate either as needed by the patient or during times of immobility (i.e. sleep).
  • the balloon-like apparatus 390 can be inflated through application of a syringe device injecting a bio-inert fluid into the balloon-like apparatus.
  • a bio-inert fluid can be phosphate buffer solution, phosphate buffered saline or hepes.
  • the pharmaceutical delivery device 10 is conducive for delivering fluid-like therapeutic composition 27 to a particular region of the brain.
  • FIGURE 8 illustrates such an application.
  • the distal end 90 of the conduit 80 is first positioned within a lateral ventricle of the brain.
  • the central assembly 20 is preferably fixated to a region of the brain directly superior to the position of conduit 80 as it resides in a ventricle of the brain.
  • central assembly 20 is implanted within the skull so that the superior surface of the central assembly 20 is flush with the superior surface of the skull.
  • Conduits 150 and 175 are then implanted into the region of the brain comprising the target site 500.
  • valve assembly 30 After the pharmaceutical delivery device 10 has been properly implanted into the brain, the openings in valve assembly 30 are arranged so that cerebral spinal fluid can travel into conduit 80 through valve assembly 30 and into the pharmaceutical reservoir 25.
  • the pressure created within pharmaceutical depot 25 by the cerebral spinal fluid causes the fluid-like therapeutic composition 27 to travel into conduit 110 and into target infuser 135.
  • target infuser 135, which is preferably fixated in the Dura mater or skull at a location superior to target site 500 the fluid-like therapeutic composition flows into conduit 150.
  • the fluid-like therapeutic composition 27 then flows through dialysis membrane 100 and contacts the damaged or diseased tissue at target site 500. As a result, the damaged and/or diseased tissue receives the necessary medication.
  • the flow of the fluid-like therapeutic composition 27 enters the target site 500, causing the pressure within target site 500 to increase because the area is limited by the surrounding tissues.
  • fluid residing within the target site 500 can flow back through the dialysis membrane 100 and enter conduit 175, which extends beyond conduit 150 at the target site 500.
  • the fluid traveling in conduit 175 can then enter shunt 200 and be vacated to a region of the body having lower pressure on the exterior surface of the body.
  • FIGURE 9 illustrates device 10 on the aortic arch.
  • the preferred location for grafting is any large artery involving high-pressure blood flow.
  • FIGURE 10 provides a more detailed illustration of device 10 in conjunction with the circulatory device.
  • Conduit 1 10 is made of an inert substance having a resilient strength similar to that of a healthy artery.
  • a preferred substance would be a biodegradable material as previously discussed, modified to be nonthrombogenic.
  • control device 250 is required to regulate the flow of the fluid-like therapeutic composition 27 to the target site 500.
  • Control device 250 is securely attached to valve assembly 30 of device 10 by control wire 265.
  • Control device 250 can thus adjust the opening of valve assembly 30 and control the flow of blood through device 10.
  • a preferred control device would be an electronic device as known by those skilled in the art of electronics. Other possible devices for controlling the opening of valve assembly 30 would be through use of a wireless remote control device.
  • the control device 250 can be located in any body cavity preferred by the surgeon.
  • FIGURE 11 depicts device 10 operating in conjunction with the intestinal device.
  • Central assembly 20 can be grafted onto the common bile duct to utilize the emulsion salts ejected by the gall bladder.
  • bile salts do not continuously flow from the gall bladder. Bile salts, rather, are ejected through contraction of the gall bladder when the volume of bile salts reaches approximately 40.0 to 70.0 mL.
  • conduit 80 (not depicted in FIGURE 11), which is surgically fixated within the interlining of the common bile duct.
  • the bile salts flow through open valve assembly 30 (also not depicted in FIGURE 1 1) and into pharmaceutical depot 25.
  • the emulsification salt can then react with the pharmaceutical agent of the fluid-like composition 27, which requires emulsification before becoming active.
  • the emulsification salts can degrade encapsulation-media material, such as in the case of lipid or polymer based microspheres used to convey the pharmaceutical agent.
  • the pharmaceutical agent then passes from the pharmaceutical reservoir 25 and into conduit 1 10, which is surgically inserted into a region of the duodenum preferred by the surgeon.
  • the pharmaceutical agent is then absorbed into the intestine and delivered to the target site through the circulatory system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un dispositif d'administration pharmaceutique permettant d'administrer un agent pharmaceutique de manière continue au niveau d'un site cible dans le corps, s'affranchissant des coûts et de la complexité inhérents à d'autres types de dispositifs d'administration. Ce dispositif d'administration pharmaceutique emploie une pression endogène du corps afin de déplacer la composition thérapeutique du réservoir vers le site cible. Par conséquent, ce dispositif peut être utilisé dans toutes les parties du corps présentant un gradient de pression (par exemple le fluide cérébro-spinal, le flux de sang, l'appareil digestif etc.). En outre, ledit dispositif d'administration pharmaceutique peut également comporter un élément de modulation de pression (300) et peut être réalisé à partir de matériaux biodégradables.
PCT/US2000/020240 1999-07-30 2000-07-26 Dispositif d'administration pharmaceutique et utilisation de celui-ci WO2001008725A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63743/00A AU6374300A (en) 1999-07-30 2000-07-26 An apparatus for pharmaceutical delivery and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14662699P 1999-07-30 1999-07-30
US60/146,626 1999-07-30

Publications (1)

Publication Number Publication Date
WO2001008725A1 true WO2001008725A1 (fr) 2001-02-08

Family

ID=22518220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020240 WO2001008725A1 (fr) 1999-07-30 2000-07-26 Dispositif d'administration pharmaceutique et utilisation de celui-ci

Country Status (2)

Country Link
AU (1) AU6374300A (fr)
WO (1) WO2001008725A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012096969A1 (fr) * 2011-01-10 2012-07-19 Colder Products Company Dispositif de distribution de fluide biodégradable
WO2022246042A1 (fr) * 2021-05-19 2022-11-24 Alcyone Therapeutics, Inc. Systèmes de distribution de fluide et procédés de traitement

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US5643207A (en) * 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US5643207A (en) * 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012096969A1 (fr) * 2011-01-10 2012-07-19 Colder Products Company Dispositif de distribution de fluide biodégradable
WO2022246042A1 (fr) * 2021-05-19 2022-11-24 Alcyone Therapeutics, Inc. Systèmes de distribution de fluide et procédés de traitement

Also Published As

Publication number Publication date
AU6374300A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
US6056725A (en) Therapeutic method for treatment of alzheimer's disease
US7189222B2 (en) Therapeutic method of treatment of alzheimer's disease
ES2314241T3 (es) Dispositivo con una parte expansible para la liberacion de farmacos.
JP4604022B2 (ja) 運搬促進デリバリー法による組織および腫瘍への液体の投与のための携帯用装置
JP6162047B2 (ja) 薬物送達装置
US5588961A (en) Electro-osmotic infusion catheter
US7069634B1 (en) Method for manufacturing a catheter
US8066690B2 (en) Method for delivering medication into an arterial wall for prevention of restenosis
US6093180A (en) Intraparenchymal infusion catheter system
US6551290B1 (en) Catheter for target specific drug delivery
US7153292B2 (en) Catheter for target specific drug delivery
US6974448B2 (en) Method for convection enhanced delivery catheter to treat brain and other tumors
US20080152694A1 (en) Devices, Systems and Methods for Ophthalmic Drug Delivery
US20030045861A1 (en) Convection enhanced delivery catheter to treat brain and other tumors
JP2014507221A5 (fr)
EP2353632B1 (fr) Dispositif médical pour l'administration locale de médicament
EP1305074A2 (fr) Catheter d'administration de medicaments specifiques de cibles
WO2012047931A1 (fr) Dispositif pour administration locale de médicament et traitement d'un œdème cérébral et autres maladies cérébrales
US7186247B2 (en) Apparatus and system for delivery of drug therapies
WO2001008725A1 (fr) Dispositif d'administration pharmaceutique et utilisation de celui-ci
US20240148950A1 (en) Dialysis catheter clearance device and associated method
WO2019195389A1 (fr) Dispositifs et procédés de remplissage et d'extraction d'un réservoir de médicament à deux lumières
CN117679614A (zh) 一种用于支撑、压迫及药物输送的压控型球囊
SE468702B (sv) Anordning foer aastadkommande av en permanent foerbindelse mellan bukvaegg och bukhaala hos maenniskor eller djur
Hoekstra Drug Delivery Systems: Technology and Clinical Applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10048811

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载